Amlodipine Use in Patients with Severe Renal Impairment

Monitoring and Dosing Considerations

• The American Heart Association recommends assessing blood pressure response after 2 weeks of amlodipine treatment, with a potential increase to 5 mg daily if inadequate control and no adverse effects are observed 1
• Peripheral edema, the most common side effect of amlodipine, occurs in up to 10% of patients but does not indicate worsening renal function, as noted by the Hypertension journal 1

Comparative Advantage and Special Considerations

• The European guidelines suggest that ACE inhibitors/ARBs are only recommended if eGFR >30 mL/min, making amlodipine a preferred option for patients with advanced CKD, as reported in the Circulation journal 4
• Amlodipine has no hyperkalemia risk and does not require potassium monitoring, according to the Hypertension journal 1
• The American College of Cardiology recommends avoiding non-dihydropyridine CCBs, such as diltiazem and verapamil, due to negative inotropic effects and increased heart failure risk, as demonstrated in the PRAISE trial and reported in the Circulation journal 6

Patient Safety and Drug Interactions

• Orthostatic hypotension is a significant concern, particularly in elderly patients with CKD, as noted by Praxis Medical Insights 2
• Amlodipine can be safely combined with ACE inhibitors/ARBs if needed for additional blood pressure control, according to Praxis Medical Insights 5